Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Oxurion to Participate in Upcoming Conferences

5 May 2022

Leuven, BELGIUM, Boston, MA, US – MAY 5, 2022Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, announced today that Tom Graney, Chief Executive Officer, will participate in two conferences in May.

Bio€quity Europe 2022
May 16 – 18, 2022
Hotel Meliá Milano, Milan, Italy
Tom Graney, CEO, and Michael Dillen, Chief Business Officer, will be available for meetings

Clinical Trials at the Summit
May 21, 2022
Hyatt Regency, Lake Tahoe, NV
Tom Graney, CEO, will speak on a panel, "Challenges of Bringing Novel Treatments to Market," at 6:30pm ET on May 21

Press release attachment: